logo
Global Scholars Converge in Hong Kong at Hong Kong Baptist University's Inaugural International Interdisciplinary Research Summit

Global Scholars Converge in Hong Kong at Hong Kong Baptist University's Inaugural International Interdisciplinary Research Summit

Inspiring Collaboration and Innovation to Drive Impactful Research Addressing Global Challenges
HONG KONG SAR - Media OutReach Newswire - 28 February 2025 - Hong Kong Baptist University (HKBU)'s inaugural International Interdisciplinary Research Summit (IIRS) has convened leading scholars, researchers, and innovators from diverse fields from Hong Kong and worldwide to foster collaboration and address pressing global challenges, particularly in fields including Data Analytics & Artificial Intelligence (AI), and Health and Drug Discovery.
Interdisciplinary Solutions: Enabling Early Identification of High-Risk Individuals for Disease Treatment
In a world where health challenges have reached unprecedented levels, HKBU's inaugural International Interdisciplinary Research Summit (IIRS) showcased how interdisciplinary collaboration, between Data Analytics & Artificial Intelligence (AI), and Health and Drug Discovery, can revolutionize and accelerate the development of new and more effective treatments for a range of diseases. As highlighted by Vice President (Research and Development) Professor Aiping Lyu, the university is dedicated to fostering international research collaboration against today's complex challenges. He noted that the university's focus on four transdisciplinary clusters - creative media and practice, health and drug discovery, analytics and AI, and humanity and culture, is crucial for fostering innovation.
Keynote speakers of the Summit included Professor Jeremy Nicholson, Director, Australian National Phenome Centre, Murdoch University, Australia; Albert Einstein Honorary Professor of Medical Biochemistry, Chinese Academy of Sciences, China; Emeritus Professor of Biological Chemistry, Imperial College London, UK. Known to be one of the world's foremost coronavirus experts, Nicholson covered the topic of 'Molecular Phenomic Approaches in Population Health and Disease Diagnosis'. He unveiled how AI and advanced data analysis are used to analyse genes and lifestyle, highlighting that studying humans for future scientific relevance requires considering the complex interplay of genes, environment, politics, funding, and human interactions that ultimately influence the translation of science into clinical medicine.
Professor Thomas Efferth, Director, Institute of Pharmaceutical and Biomedical Sciences, and Chair, Department of Pharmaceutical Biology, Johannes Gutenberg University, Germany, leads a research team developing compounds that could replace opioids as pain relief without addiction. In the speech titled 'Artificial Intelligence and Network Biomedicine in Natural Product Research', Efferth highlighted the transformative role of AI and systems biology in natural product research, explaining that tasks previously performed manually by generations of PhD students, such as pipetting in wet labs, can now be automated with robots. Moreover, AI can optimize experiment design, creating significant opportunities for deep learning and AI in research.
Likewise, Professor Gavin Winston, Department of Medicine, Centre for Neuroscience Studies and School of Computing, Queen's University, Canada, is leveraging AI and ML to revolutionise brain imaging for neurological diagnosis and treatment. In his presentation titled 'Machine Learning in Neuroimaging across Disciplines', he highlighted how advanced techniques like deep learning are enabling more efficient and precise analysis of MRI and CT scans, ultimately leading to improved outcomes. Notably, his current research focuses on utilising robotics and neuroimaging to understand and address cognitive impairment in individuals with epilepsy, demonstrating a commitment to improved patient care.
Professor Jianfeng Feng, Dean of the Institute of Science and Technology for Brain-Inspired Intelligence and School of Data Science at Fudan University, spoke on the topic 'From Multi-Omic Data to Brain Diseases, Digital Twin Brains, and Brain-Inspired AI'. One of Feng's research projects found that blood biomarkers can forecast the risk of dementia 15 years before diagnosis of Alzheimer's disease. He emphasised that AI and ML are transforming healthcare, from understanding the foundations of diseases to developing personalised medicine.
The summit's panel discussions further amplified the impact of interdisciplinary approaches in disease treatment. Leading experts delved into crucial discussions, enriched by perspectives on natural products and Traditional Chinese Medicine, centred on the challenges and way forward in translating big data into actionable understanding. Key topics included integrating Al capabilities with domain knowledge for data-driven model interpretation, addressing the paradox of using doctor-labelled data for Al training in clinical applications, managing multi-scale parameter calibrations and validations in principle-based modelling, and balancing computational cost with biological predictability through strategic coarse-graining. These sessions generated a wealth of new perspectives and underscored the indispensable role of science in addressing societal health challenges.
Professor Johnny Poon, Associate Vice-President (Interdisciplinary Research), HKBU, remarked that the IIRS cultivated a vibrant atmosphere for sharing knowledge and working together. Scholars have gathered and expressed enthusiasm for the groundbreaking research expected to result from the relationships formed at the summit.
As one of the priorities of the University's Institutional Strategic Plan 2018-2028, HKBU aspires to be a leading, research-led, liberal arts University in Asia. The University keeps enhancing its capacity and strength to produce world-class research with an aim to bring significant impact to society. To learn more about HKBU's research strengths and our publications, visit HKBU Research Website.
Hashtag: #HKBU
The issuer is solely responsible for the content of this announcement.
About HKBU Research Office
At Hong Kong Baptist University (HKBU), we nurture and uphold a robust research culture and environment, and equip our remarkable researchers with visionary insights and strategic experiences throughout their intellectual journey. While promulgating our esteemed researchers, their interdisciplinary research initiatives, and HKBU's research excellence locally and internationally, we value our solid connections with the HKBU community.
Together with every community member, we strive for research excellence in our four strategic research clusters: Creative Media and Practice, Health and Drug Discovery, Data Analytics and Artificial Intelligence, and Humanities and Cultures.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Apex Labs Granted Israel MoH Approval to Expand Phase 2b Macrodose Psilocybin PTSD Clinical Trial
Apex Labs Granted Israel MoH Approval to Expand Phase 2b Macrodose Psilocybin PTSD Clinical Trial

Yahoo

time3 days ago

  • Yahoo

Apex Labs Granted Israel MoH Approval to Expand Phase 2b Macrodose Psilocybin PTSD Clinical Trial

Israel's Ministry of Health (MoH) approval to add additional sites to APEX SUMMIT-90 160 patient phase 2b macrodose clinical trial: Tel Aviv University (TAU)'s Institute for Psychedelic Research located at the Sagol Brain Institute (SGI) in Tel-Aviv Sourasky Medical Center. Be'er Yaakov Mental Hospital (Merhavim) Center for Psychedelic Studies. For more information or to register visit (Canada) and (Israel). VANCOUVER, British Columbia, June 12, 2025 (GLOBE NEWSWIRE) -- Apex Labs Ltd. (APEX or the Company), a pharmaceutical company transforming the standard of mental health care with psilocybin is pleased to announce the approval by the Israeli MoH and IRBs to open two additional clinical trial sites for SUMMIT-90. The trial is a double-blind, placebo controlled phase 2b study evaluating multiple doses of APEX-90, a psilocybin macrodose utilizing APEX's US patent pending capsule. APEX-90 is administered in-clinic with study-assisted psychotherapy for severe depression within diagnosed PTSD. Israel is facing a severe mental health crisis: 44% of adults report depression and 42% PTSD, far above the 8–13% depression and 6–10% PTSD rates seen in the US and Canada. This MoH approval leverages the expertise of TAU's renowned SGI and Merhavim Hospital, which both have a rich history of pioneering research in neurological sciences. Their cutting-edge facilities and teams profound understanding of PTSD dynamics are poised to add patient recruitment expertise. 'I am honoured to have been able to facilitate this new partnership; another example of building important bridges between Canada and Israel in innovative clinical research, which will result in advancing patient access to emerging treatments,' says Sharon J. Fraenkel, TAU Canada's CEO for Ottawa, Quebec, and Atlantic Canada, on behalf of the organization. 'As someone deeply connected to Israel, witnessing the toll of PTSD among my loved ones, I'm driven to lead research that brings hope and healing,' says Alysa Langburt, APEX's VP of Global Clinical Development. 'This marks more than a clinical milestone, it represents a fundamental step towards transforming the mental health landscape in Canada and Israel, where the need has never been greater. Through our incredible partnerships, we aim to catalyze a shift in access, care and outcomes for those suffering with PTSD.' "SUMMIT-90 offers a beacon of hope for the significant numbers suffering from PTSD in Canada and Israel,' says Tyler Powell, co-Founder and CEO of APEX. 'It underscores our commitment to global mental health innovation and our belief in the opportunity for clinically proven psilocybin therapies to transform mental health care.' About Apex Labs is a patient-driven pharmaceutical company focused on revolutionizing the standard of mental health care with psilocybin. APEX's strategy is two-pronged, clinical evaluation of drug assets alongside a robust Early Access Program. APEX recognizes and prioritizes Veterans as a patient base with the most severe unmet medical need. Visit for more information and follow APEX on LinkedIn, Twitter and Instagram. Forward-Looking StatementsThis release contains certain "forward-looking statements" and certain "forward-looking information" as defined under applicable Canadian securities laws. Forward-looking statements and information can generally be identified by the use of forward-looking terminology such as "may", "will", "expect", "intend", "estimate", "anticipate", "believe", "continue", "plans" or similar terminology. Forward-looking statements and information are based on forecasts of future results, estimates of amounts not yet determinable and assumptions that, while believed by management to be reasonable, are inherently subject to significant business, economic and competitive uncertainties and contingencies. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability to control or predict, that may cause the Company's actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out here in, including but not limited to: receiving authorization of Health Canada Dealers Licence; filing US provisional patent, the Company evaluating the safety and efficacy of APEX-52 (psilocybin) and APEX-90 (psilocybin) in treating depression in Veterans and patients with Post-Traumatic Stress Disorder; statements related to APEX-52 and APEX-90, including manufacturing, dosing, and trial details; statements made by the Company's executives with respect to Health Canada's Dealer's Licence and capsule patent filing; the Company's efforts around the Early Access Program; statements made relating to Canadian Veteran patients; approvals by the Israeli Ministry of Health and ethics; the inherent risks involved in the general securities markets; uncertainties relating to the availability and costs of financing needed in the future; the inherent uncertainty of cost estimates and the potential for unexpected costs and expenses, currency fluctuations; regulatory restrictions, liability, competition, loss of key employees and other related risks and uncertainties. The Company undertakes no obligation to update forward-looking information except as required by applicable law. Such forward-looking information represents managements' best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information. SOURCE Apex Labs Ltd. CONTACT: For further information: info@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Global Longevity Summit 2025: Spotlight on Dr. Steve Horvath, New Advisory Board Members, and Early Registration Opportunity
Global Longevity Summit 2025: Spotlight on Dr. Steve Horvath, New Advisory Board Members, and Early Registration Opportunity

Yahoo

time3 days ago

  • Yahoo

Global Longevity Summit 2025: Spotlight on Dr. Steve Horvath, New Advisory Board Members, and Early Registration Opportunity

Informa Connect's Global Longevity Summit continues to break new ground in the science of aging and human performance with the announcement of its 2025 keynote speaker, new advisory board appointments, and a call to act before the upcoming ticket price increase. GENEVA, SWITZERLAND, June 12, 2025 (GLOBE NEWSWIRE) -- Biogerontologist and epigenetic researcher Dr. Steve Horvath will headline the event as its keynote speaker and will be formally recognized as the recipient of the 2025 Global Longevity Award for his exceptional work in the development of the epigenetic clock - a breakthrough that continues to reshape our understanding of biological aging and predictive biomarkers. The Global Longevity Summit convenes from October 28–30, 2025, at the Genolier Innovation Hub in Geneva, Switzerland. The event brings together a distinguished cohort of 300 global leaders across healthcare, science, business, and capital. Under this year's theme, 'Mastering the Aging Clock: The Science of Longevity,' the program will feature cutting-edge insight into epigenetics, regenerative medicine, AI-powered health optimization, and precision intervention strategies. The Summit also expands its leadership circle with new Scientific and Professional Advisory Board members, each selected for their expertise in advancing healthy human lifespan. These new appointments reinforce the event's global vision and commitment to multidisciplinary innovation. This year's event is shaping up to be the most anticipated yet - and with demand rising, early registration is strongly encouraged. Ticket prices will increase on July 1, and delegate spots are limited. Interested participants are urged to secure access now to avoid missing this landmark opportunity. The Global Longevity Summit is an invitation-only event requiring participant approval. Qualified professionals and executives in the longevity ecosystem may apply to join at About the Global Longevity SummitThe Global Longevity Summit is the definitive gathering of international leaders dedicated to advancing human longevity through scientific innovation and strategic collaboration. The invitation-only conference unites experts, entrepreneurs, and investors to accelerate breakthroughs in life extension and power the future of healthy aging. CONTACT: Drew Wilson Global Longevity Summit (+1) 713-725-8983

Summit Spine Continues Expansion into North Carolina, Partners with Dr. Louis Torres
Summit Spine Continues Expansion into North Carolina, Partners with Dr. Louis Torres

Associated Press

time3 days ago

  • Associated Press

Summit Spine Continues Expansion into North Carolina, Partners with Dr. Louis Torres

'We are thrilled to welcome Dr. Louis Torres to our team as we continue to enhance access to advanced pain care for the Fayetteville community.'— Dr. Amit Patel, CEO and Founder of Summit Spine & Joint Centers FAYETTEVILLE, NC, UNITED STATES, June 12, 2025 / / -- Summit Spine & Joint Centers, a leading multi-location provider of minimally invasive spine care, proudly announces the appointment of Dr. Louis Torres as the newest physician leader. Dr. Torres will support Summit's growing North Carolina operations – which operate under the Integrated Pain Solutions brand. Dr. Torres' arrival represents a strategic milestone in the organization's continued commitment to delivering best-in-class musculoskeletal (MSK) solutions to the Fayetteville region. With an established presence spanning 30 locations in Georgia, 11 in North Carolina, one in Tennessee, and two in South Carolina, Summit Spine & Joint Centers has earned widespread recognition for its excellence in pain management and compassionate patient care. The addition of Dr. Torres strengthens the Company's dedication to expanding access to high-quality, patient-focused care for individuals suffering from chronic pain across the Southeast. Specializing in the diagnosis and treatment of complex conditions—including neck and back pain, sciatica, herniated discs, headaches, pelvic and musculoskeletal pain, and neuropathic disorders—Summit Spine leverages state-of-the-art technologies to deliver precision-based care tailored to each patient's needs. 'We are thrilled to welcome Dr. Louis Torres to our team as we continue to enhance access to advanced pain care for the Fayetteville community,' said Dr. Amit Patel, CEO and Founder of Summit Spine & Joint Centers. 'Our team of highly skilled physicians, nurses, and support staff are united by a shared mission: to improve lives by relieving pain and restoring function through innovative, minimally invasive treatments.' Dr. Torres, a Fayetteville-based physician with strong ties to the region, shared his enthusiasm for the partnership: 'I'm honored to expand access to advanced pain care in a community that means so much to me. Summit's focus on cutting-edge technology and its collaborative, patient-centered approach ensures that each patient receives the highest level of comprehensive and compassionate care.' Summit Spine & Joint Centers operates 17 ASCs and 44 clinics across four (4) states, with Georgia locations in Athens, Augusta, Braselton, Buford, Canton, Carrollton, Cartersville, Columbus, Commerce, Conyers, Covington, Cumming, Dalton, Decatur, East Cobb, Gainesville, Jasper, Johns Creek/Norcross, Lawrenceville, Lithia Springs, Newnan, Ringgold/Ft. Oglethorpe, Rome, Roswell, Savannah, Snellville, Stockbridge, Stonecrest/Lithonia, Winder, and Woodstock; North Carolina clinics in Asheboro, Beaufort, Fayetteville, Jacksonville, Laurinburg (2), Rockingham, Southern Pines, Wadesboro, Whiteville, and Wilmington; clinics South Carolina locations in Greenville and Spartanburg; and a clinic in Chattanooga, Tennessee. For more information call (864) 383-0669 or visit Samantha Montague Summit Spine & Joint Centers +1 404-784-5318 email us here Visit us on social media: LinkedIn Instagram Facebook Legal Disclaimer: EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store